Tarceva. ICORG 08-41
NCT01721252 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 200
Last updated 2015-03-30
Summary
The aim of this study is to determine prospectively the value of a recently identified proteomic signature in identifying those patients with lung cancer, who are likely to benefit from and respond favourably to erlotinib therapy.
This is a prospective study of serum proteomics as a predictor of response to erlotinib therapy.
Conditions
Sponsors & Collaborators
-
Cancer Trials Ireland
lead NETWORK
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2009-12-31
- Primary Completion
- 2013-08-31
Countries
- Ireland
Study Locations
More Related Trials
-
An Observational Study of Tarceva (Erlotinib) in First Line in Patients With Advanced EGFR Mutation-Positive Non-Small Cell Lung Cancer (GERTAC)
NCT01790217 ·Status: COMPLETED
-
A Study Examining Long Response in Lung Cancer Patients Treated With Tarceva (Erlotinib)
NCT02133508 ·Status: COMPLETED
-
A Study of Tarceva (Erlotinib) in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer Who Present EGFR Mutations
NCT01287754 ·Status: COMPLETED ·Phase: PHASE4
-
A Study of Erlotinib in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
NCT01667562 ·Status: COMPLETED ·Phase: PHASE3
-
Surgery for Early Lung Cancer With Preoperative Erlotinib (Tarceva): A Clinical Phase II Trial (SELECT)
NCT00462995 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of Tarceva (Erlotinib) in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer Following 4 Cycles of Platinum-based Chemotherapy Without Disease Progression
NCT01230710 ·Status: COMPLETED ·Phase: PHASE4
-
A Study of Tarceva (Erlotinib) in Patients With Locally Advanced, Metastatic or Recurrent Non-Small Cell Cancer Who Present Epidermal Growth Factor Receptor Mutations
NCT01372384 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of Erlotinib (Tarceva) Versus Gemcitabine/Cisplatin as First-line Treatment in Patients With Non-small Cell Lung Cancer With EGFR Mutations
NCT01342965 ·Status: COMPLETED ·Phase: PHASE3
-
Proteomic Profiling in Predicting Response in Patients Receiving Erlotinib for Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer
NCT00550537 ·Status: COMPLETED ·Phase: PHASE2
-
An Observational Study of Tarceva (Erlotinib) in Routine Practice For First Line Maintenance Therapy in Patients With Non Small Cell Lung Cancer
NCT01194050 ·Status: COMPLETED
-
A Study of Tarceva (Erlotinib) to Compare Two Different Doses in in Currently Smoking Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (CURRENTS)
NCT01183858 ·Status: COMPLETED ·Phase: PHASE3
-
Study of Erlotinib (Tarceva®) in Combination With OSI-906 in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) With Activating Mutations of the Epidermal Growth Factor Receptor (EGFR) Gene
NCT01221077 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Assess the Incidence of EGFR Mutation in Patients With Newly Diagnosed Locally Advanced or Metastatic Non-Small Cell Lung Cancer in the UK, And of Tarceva (Erlotinib) as First-Line Therapy in EGFR Mutation Positive Patients.
NCT01250119 ·Status: COMPLETED ·Phase: PHASE2
-
Phase I/II Study of Chemoprevention With EGFR and COX-2 Inhibitor
NCT00314262 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Erlotinib (Tarceva) as a Single Agent or Intercalated With Combination Chemotherapy in Patients With EGFR Positive NSCLC
NCT00294762 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of First Line Treatment With Tarceva (Erlotinib) in Combination With Gemcitabine in Patients With Unresectable Advanced and/or Metastatic Non-Small Cell Lung Cancer
NCT00701558 ·Status: COMPLETED ·Phase: PHASE2
-
Erlotinib as First-line Treatment of Advanced Non-small Cell Lung Cancer (NSCLC) for Patients Unfit for Chemotherapy
NCT00452075 ·Status: TERMINATED ·Phase: PHASE2
-
An Observational Study of Tarceva (Erlotinib) in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer With Wild-Type Epidermal Growth Factor Receptor (EGFR) Gene (WILT)
NCT01512420 ·Status: COMPLETED
-
A Non-interventional Trial of Erlotinib (Tarceva) Metastatic Non-small Cell Lung Cancer
NCT02595450 ·Status: COMPLETED
-
A Phase 2 Study of Tarceva for Untreated, Good Prognosis Patients With Advanced Non-Small Cell Lung Cancer
NCT00585533 ·Status: COMPLETED ·Phase: PHASE2
-
A Study on the Correlation Between Tarceva (Erlotinib) - Induced Rash and Efficacy in EGFR Mutated Participants With Advanced Non-Small Cell Lung Cancer Receiving First-Line Therapy
NCT01174563 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of First or Second Line Treatment With Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer
NCT01066884 ·Status: COMPLETED ·Phase: PHASE4
-
A Study of Tarceva (Erlotinib) in First Line in Patients With Locally Advanced or Metastatic Lung Adenocarcinoma With EGFR Mutations
NCT01609543 ·Status: COMPLETED ·Phase: PHASE4
-
Erlotinib vs. Standard Chemotherapy in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) and Eastern Cooperative Oncology Group (ECOG)Performance Status (PS) 2
NCT00085839 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of Serum Protein Profiling in Patients With Non-Small Cell Lung Cancer Treated With Gefitinib or Erlotinib
NCT00717847 ·Status: COMPLETED